Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Phathom Pharmaceuticals, Inc. (PHAT) had Revenue of $55.25M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$55.25M
Net Income	$-334.33M
Cost of Goods Sold	$7.97M
Gross Profit	$47.28M
Operating Expenses	$332.72M
Operating Income	$-277.47M
Non-Operating Income/Expense	$-56.86M
Pre-Tax Income	$-334.33M
Normalized Pre-Tax Income	$-334.33M
Income after Taxes	$-334.33M
Income from Continuous Operations	$-334.33M
Consolidated Net Income/Loss	$-334.33M
Normalized Income after Taxes	$-334.33M
EBIT	$-277.47M
EBITDA	$-274.48M
Weighted-Average Shares Outstanding (Basic)	63.18M
Weighted-Average Shares Outstanding (Diluted)	63.18M
Earnings per Share (EPS) (Basic)	$-5.29
Earnings per Share (EPS) (Diluted)	$-5.29
Balance Sheet Financials
Current Assets	$360.13M
Property, Plant, and Equipment	$1.48M
Long-Term Assets	$18.18M
Total Assets	$378.32M
Current Liabilities	$85.73M
Long-Term Debt	$201.41M
Long-Term Liabilities	$546.17M
Total Liabilities	$631.90M
Common Equity	$-253.58M
Tangible Shareholders Equity	$-253.58M
Shareholders Equity	$-253.58M
Common Shares Outstanding	68.52M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-266.77M
Cash Flow from Investing Activities	$-0.14M
Cash Flow from Financial Activities	$182.77M
Beginning Cash	$384.26M
End Cash	$300.12M
Increase/Decrease in Cash	$-84.13M
Stock-Based Compensation	$24.05M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.20
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-3.86
Debt to Equity Ratio	-0.79
Gross Margin	85.57%
Operating Margin	-502.18%
EBIT Margin	-502.18%
EBITDA Margin	-496.78%
Pre-Tax Profit Margin	-605.09%
Profit Margin	-605.09%
Free Cash Flow	$-266.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	2.49
Receiveable Turnover	1.42
Days Sales in Receivables	256.30
Return on Equity	131.84%
Return on Tangible Equity	131.84%
Return on Assets	-88.37%
Return on Investments	640.83%
Book Value Per Share	$-3.70
Free Cash Flow per Share	$-4.22
Operating Cash Flow per Share	$-4.22

Data from Zacks Investment Research, Inc.